L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

Acute Lymphoblastic Leukemia Clinical Trial

Official title:

A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01910428
• Other study ID #: GRASPALL 2012-09
• Status: Terminated
• Phase: Phase 1
• Start date: October 2013
• Est. completion date: March 2018

Study information

• Verified date: July 2018
• Source: ERYtech Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Asparaginase (Asp) is used during the induction phase of ALL treatment for children and young adults. Its efficacy is counterbalanced by its toxicity, mainly in patients 40 years or older. The efficacy rate in older adult population is lower than for children or young adults. A recent review on outcomes in older adults with ALL pointed out that there were significantly more drug reductions, omissions or delays in the older group as compared to younger adults and that asparaginase was the drug most commonly omitted.

The investigational product ERYASPASE is a dispersion for infusion of homologous red blood cells (RBC) encapsulating E. coli L-asparaginase.

A previous European phase I/II clinical study in children and adults (<55 yo) at first relapse of ALL was conducted to determine the optimal dose of homologous RBC encapsulating native E. coli Asp (GRASPA®) in 24 patients with relapsed ALL. The activity and safety profiles of 3 doses of GRASPA® (50, 100 and 150 IU/kg) in combination with standard chemotherapy were compared to free native Asp. The global safety profile is also improved, reducing hypersensitivity, liver toxicity and coagulation disorders. Study showed that a single dose of GRASPA® 150 IU/kg induced a depletion in plasmatic asparagine for 18.6 days, i.e. similar to that obtained with 8 injections of 10,000 IU/m² of free native Asp. A reduction in the incidence and severity of the allergic reactions and coagulation disorders were observed with GRASPA® (Domenech 2011).

A French phase II study designed to determine the maximum tolerated dose of GRASPA® in combination with a polychemotherapy regimen in ALL patients older than 55 yo at first diagnosis has been performed, and showed that both 100 and 150 IU/kg doses fulfilled the predefined criteria for efficacy and tolerability but the better profile of 100 IU/kg dose was considered the optimal dose in this setting. A phase II/III trial in adult and children patients with relapsed ALL is currently ongoing.

Based on these results, the combination of ERYASPASE with the CALGB chemotherapy regimen appears to be an attractive combination for the treatment of adults patients with ALL/LBL.

Description:

A phase I study to assess the limiting toxicities, global safety and clinical activity of ERYASPASE, using a dose titration design to confirm that the safety profile of ERYASPASE in combination with the CALGB chemotherapy regimen is similar to that observed in the European chemotherapy regimen. PK/PD and immunogenicity parameters will also be evaluated.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: March 2018
• Est. primary completion date: January 25, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women aged 18 years and over

• Diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma

• Received no more than 1 prior treatment for ALL/LBL

• Note: Patients who have received transplant during 1st remission are excluded since this would be considered a 2nd treatment

• ECOG performance status 0-2

• Signed Informed Consent Form

Exclusion Criteria:

• Other serious medical illness other than that treated by this study which would limit survival to <2 years or psychiatric conditions which would prevent informed consent or compliance with treatment.

• Presenting with a general or visceral contraindication to intensive treatment including:

• uncontrolled or severe cardiovascular disease, including recent (<6 months) myocardial infarction or congestive heart failure,

• Current Grade 3 or higher coagulopathy, thrombosis and/or hemostasis disorders,

• Serum creatinine concentration, 1.5 times greater than the upper limit of laboratory normal ranges (ULN), except if related to ALL/LBL,

• total bilirubin 1.5 times greater than the ULN, except if related to ALL/LBL,

• transaminases (AST or ALT) levels, 5 times greater than the ULN, except if related to ALL/LBL,

• An uncontrolled bacterial, viral, or fungal infection or an active duodenal ulcer, until these conditions are corrected or controlled.

• History of Grade 3 or higher allergic reaction with prior asparaginase treatment,

• History of allergy to penicillin or related antibiotic

• History of Grade 3 or higher blood transfusion incident according to US Biovigilance Network which refers to any transfusion followed by a major intervention (vasopressors, intubation, transfer to intensive care) to prevent death.

• Presenting with anti-erythrocyte antibodies leading to the unavailability of phenotype compatible red blood cells.

• Participation in a clinical study involving receipt of an investigational drug during the last 30 days.

• Women of childbearing potential without effective contraception as well as pregnant or breast feeding women.

• Patient receiving treatment likely to cause hemolysis or under phenytoin treatment.

• Patient undergoing yellow fever vaccination.

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Leukemia
• Leukemia, Lymphoid
• Lymphoblastic Lymphoma
• Lymphoma
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Intervention

Drug:
• L-asparaginase encapsulated in RBC
50 IU/kg IV 100 IU/kg IV 150 IU/kg IV 200 IU/kg IV

Locations

Country	Name	City	State
United States	University of Maryland, Greenebaum Comprehensive Cancer Center	Baltimore	Maryland
United States	University of Chicago	Chicago	Illinois
United States	Ohio State University	Columbus	Ohio
United States	Duke University	Durham	North Carolina
United States	Monter Cancer Center	Lake Success	New York

Sponsors (1)

Lead Sponsor	Collaborator
ERYtech Pharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Response to treatment	Hematological Complete Response rate	Induction and consolidation phases
Primary	Determination of the Maximal Total Dosage (MTD) based on number of patients presenting with related DLT	ERYASPASE administered during the induction and consolidation phases of the standard multi-agent CALBG chemotherapy	Duration of study
Secondary	Overall safety and tolerability	Number, incidence, type, severity, outcome and causality of AE and SAE	Duration of study
Secondary	Plasma concentrations of asparagine,aspartate,glutamine and glutamate.	Pharmacodynamic parameters (PD)	Induction and consolidation phases
Secondary	Optional samples for CSF levels of amino acids	PD parameters	Induction and consolidation phases
Secondary	Red blood cell 24-hour recovery analysis , total, free and encapsulated L-asparaginase	Pharmacokinetic parameter	Day of administration and 24h post administration
Secondary	Immunogenicity	Evaluation of the titer of the anti-asparaginase antibody	Duration of study